Compare Recursion Pharmaceuticals Inc (RXRX) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Wendys Co — how do they compare? Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B), while Wendys Co trades at $6.21 (market cap $1.19B). The key difference: Recursion Pharmaceuticals Inc is the larger of the two by market cap, and Wendys Co pays a 4.49% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Wendys Co for 77 Days on average.
| RXRX | WEN | |
|---|---|---|
Market Cap | $2.14B | $1.19B |
Volume | 30,789,535 | 5,622,905 |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $9.33 |
52-Week Low | $2.84 | $6.10 |
Typical Hold Time | 22 Days | 77 Days |
Enterprise Value | $1.66B | $4.92B |
Dividend Yield | — | 4.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Wendy's stock (WEN) trades at $6.11, down 0.81% on the day, reflecting ongoing pressure from declining sales and a major franchisee bankruptcy. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal a low P/E of 9.45 and strong ROE of 108.04%, but net income margins have fallen to 5.72%. Recent news highlights competitive struggles and store closures, though the company continues to beat earnings expectations.
The outlook remains cautious due to operational headwinds and high debt, but the current valuation may appeal to value investors. Risks include franchisee instability and intense competition. Analyst consensus is mixed with a $7.58 price target, suggesting limited upside from current levels amid uncertain recovery prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
